Skip to main content

Lupus

Dr. John Cush
@RheumNow
Sjögren’s and SOB? Think About ILD! While we excitedly await FDA approval of novel immunotherapies, it is worth reminding ourselves that the new drugs will be indicated primarily for patients with active systemic manifestations of SjD that is of at least moderate severity based https://t.co/T51dAyRpcw
Dr. John Cush
@RheumNow
CD19 CAR-T Relapse: 7 of 50 in Erlangen, Rescued With BCMA Relapse after CD19 CAR-T was rare in lupus and common in anti-synthetase syndrome and Scl-70 scleroderma. Six of seven relapsing patients were treated with BCMA-directed therapy and responded again. https://t.co/SCD9wZ5DVa
Dr. John Cush
@RheumNow
Not All Pain in Rheumatic Disease is Inflammatory In a session at the Global Rheumatology Summit, Dr. Daniel Clauw, an expert on the topic, explained that fibromyalgia can occur in isolation in a “top-down” fashion, or can be secondary to inflammatory autoimmune diseases in a https://t.co/AMUm52SKsB
Dr. John Cush
@RheumNow
One Diagnosis, Different Diseases: Is TLR7/8 Inhibition the Future of Lupus Treatment? We call it systemic lupus erythematosus (SLE), but are we really treating one disease? Increasingly, I wonder whether grouping biologically distinct patients under one diagnosis is limiting https://t.co/EkudaG7YiY
Dr. John Cush
@RheumNow
“Age old” biomarkers in ILD and pulmonary fibrosis At #ACR26, there was a poster on senescence being increased in SARD-ILD (systemic autoimmune rheumatic disease – interstitial lung disease) including fibrotic (progressive pulmonary fibrosis), showing epithelial remodeling from https://t.co/cNxgqJIH8T
Dr. John Cush
@RheumNow
Making the Case for Early Biologics in Lupus A new diagnosis of SLE can be overwhelming for patients. The decision to initiate biologic versus non-biologic therapy early in the disease course may have far-reaching implications for disease control, glucocorticoid exposure, and https://t.co/CmTeHTwzZw
Dr. John Cush
@RheumNow
One Diagnosis, Different Diseases: Is TLR7/8 Inhibition the Future of Lupus Treatment? We call it systemic lupus erythematosus (SLE), but are we really treating one disease? Increasingly, I wonder whether grouping biologically distinct patients under one diagnosis is limiting https://t.co/30MGwIRUgO
Dr. John Cush
@RheumNow
Cardiovascular Risk in Rheumatoid Arthritis What is the link between cardiovascular risk and dementia? In abstract 1454, Michelle Allen and colleagues at Mayo Clinic studied 2,483 adults with incident RA diagnosed between 1980 and 2019. Patients were followed for Alzheimer’s https://t.co/JaITrlZXIt
Dr. John Cush
@RheumNow
Scary IPAF IPAF describes patients who have ILD plus clinical, serologic, or morphologic features of autoimmunity but who do not meet criteria for a defined connective tissue disease. The 2015 ERS/ATS criteria proposed IPAF as a research classification, not a distinct disease, https://t.co/v3ir4IHia7
anita
@docdhanrajani

@RheumNow #3. Abstract 0041. Can CAR-T therapy truly “reset” the immune system in lupus? Promising findings show that both patient and donor-derived CAR-T suppress key inflammatory gene signatures in SLE, suggesting a molecular immune reset beyond clinical remission. #ACR26

anita
@docdhanrajani
@RheumNow #4. Continuing the conversation on unmet needs in cSLE. Abstract 2486. The PLUMM trial highlights barriers to clinical trial enrollment in pediatrics. Strict eligibility criteria, patient preference, logistic and feasibility issues limit participation. #ACR2026
anita
@docdhanrajani
@RheumNow My top 5 from #ACR2026. #5. Abstract 2484. Addressing unmet needs in cSLE using #CARRA registry data. cSLE patients have significant burden of unmet therapeutic needs with currently approved therapies. Urgent call to expedite regulatory approvals of cSLE therapies!
anita
@docdhanrajani
@RheumNow Abstract #2483 Pediatric Sjögren’s lacks validated clinical trial endpoints, limiting treatment research. This study developed a prioritized, 8-domain patient-centered endpoint for N-of-1 trials, bridging objective disease activity and lived symptom burden. #ACR26
Daric Mueller, PA-C
@rheumPAC
(2/2) LB22 Both DAZ arms with similar AEs compared to placebo group Signal for symptom response at 4W? Improved pt reported sicca outcomes with 1500mg Q4W dose vs placebo @RheumNow #ACR26
Daric Mueller, PA-C
@rheumPAC
(1/2)#ACRBest Dazodalibep (DAZ) for systemically active SjD Ph3 top line results! LB22 648 pts IV DAZ 1500mg Q4W or 3000mg Q12W vs placebo Signf improved ESSDAI in both DAZ arms @ 48W. ESDAI differences vs placebo -1.8 for 1500mg Q4W, -1.4 for 3000mg Q12W @RheumNow #ACR26
Akhil Sood MD, MS
@AkhilSoodMD
Abstract 2969: surveyed pts w/ lupus about clinical trial awareness - 87% patients reported informed about their dx w/ physicians as main source (94%) - cliniical trial knowledge lower (44%) - 84% expressed interest in trials - travel most common barrier @RheumNow #ACR26
×